Enfortumab vedotin - Agensys/Seattle Genetics

Drug Profile

Enfortumab vedotin - Agensys/Seattle Genetics

Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab vedotin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agensys; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urogenital cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Urogenital-cancer(Metastatic disease, Second-line therapy or greater) in Canada (IV, Infusion)
  • 03 Nov 2017 Astellas Pharma initiates enrolment in the phase Ib EV-103 trial for Urogenital cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03288545)
  • 10 Oct 2017 Astellas Pharma and Seattle Genetics dose first patient in the phase II EV-201 trial for Urogenital cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top